Table 2.
Cases N (%) | Controls N (%) | Crude OR (95% CI) | Adjusted * OR (95% CI) | Adjusted** OR (95% CI) | |
---|---|---|---|---|---|
No estrogen therapy | 1103 (87.4) | 10,850 (86.0) | 1 | 1 | 1 |
Estrogen therapy concurrent with AI | 48 (3.8) | 404 (3.2) | 1.17 (0.86–1.58) | 0.84 (0.61–1.16) | 0.87 (0.62–1.22) |
Estrogen therapy concurrent with tamoxifen | 44 (3.5) | 287 (2.3) | 1.50 (1.09–2.08) | 1.26 (0.89–1.79) | 1.30 (0.91–1.86) |
Estrogen therapy concurrent with both AI and tamoxifen as sequential therapy | 29 (2.3) | 230 (1.8) | 1.23 (0.83–1.83) | 1.10 (0.73–1.67) | 1.14 (0.74–1.74) |
Estrogen therapy without concurrent AI or tamoxifen | 38 (3.0) | 849 (6.7) | 0.44 (0.31–0.61) | 0.61 (0.43–0.86) | 0.61 (0.43–0.87) |
OR odds ratio, CI confidence interval
*Adjusted for age, time from breast cancer diagnosis to index date, T stage, N stage, and chemotherapy
**Adjusted for variables in previous adjustment*, as well as educational level, family income, marital status, CCI, DCI, previous estrogen therapy exposure, region